<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246164</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00035757</org_study_id>
    <nct_id>NCT04246164</nct_id>
  </id_info>
  <brief_title>A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo Controlled Pilot Trial of the Feasibility of High Definition Transcranial Direct Current Stimulation and Cognitive Training in Patients With Mild Cognitive Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this project is to assess the feasibility of multi-field, extended&#xD;
      HD-tDCS (MFE-HD-tDCS) with simultaneous computerized CT as a viable intervention to improve&#xD;
      cognitive function in patients with MCI. This double-blinded, randomized pilot clinical trial&#xD;
      of repetitive daily HD-tDCS/sham HD-tDCS, administered in combination with CT to subjects&#xD;
      with MCI in 3 monthly blocks of 5 daily sessions for a total of 15 sessions will enroll 8&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment completion rates</measure>
    <time_frame>6 months</time_frame>
    <description>This pilot study would prove the feasibility of the proposed approach. Treatment completion rates of less than 75% could be reasonably excluded if all 8 patients are observed to complete the 6 month treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>3 months</time_frame>
    <description>Recruiting and consenting 8 patients over a period of 3 months would support the feasibility of conducting a larger-scale, 2-site, phase II trial with 120 MCI patients over a span of 5 years (i.e. approximately 32 patients/year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Memory Disorders</condition>
  <condition>Memory Loss</condition>
  <arm_group>
    <arm_group_label>HD-tDCS combined with CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham HD-tDCS combined with CT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HD-tDCS combined with CT</intervention_name>
    <description>HD-tDCS treatments will be administered during a cognitive training session.</description>
    <arm_group_label>HD-tDCS combined with CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham HD-tDCS combined with CT</intervention_name>
    <description>sham-HD-tDCS treatments will be administered during a cognitive training session.</description>
    <arm_group_label>sham HD-tDCS combined with CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥50-90 years&#xD;
&#xD;
          2. Right handed&#xD;
&#xD;
          3. Willing and able to undergo all procedures&#xD;
&#xD;
          4. Retains decisional capacity at initial visit&#xD;
&#xD;
          5. Meets criteria for MCI, amnestic type (Petersen, 2004).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Left handed patients&#xD;
&#xD;
          2. Significant kidney injury requiring hemodialysis&#xD;
&#xD;
          3. Automatic Internal Cardiac Defibrillator (AICD) or Pacemaker&#xD;
&#xD;
          4. Significant congestive heart failure&#xD;
&#xD;
          5. History of clinically significant ischemic or hemorrhagic stroke, or lacune or infarct&#xD;
             considered by radiologist likely to cause or contribute significantly to cognitive&#xD;
             symptoms&#xD;
&#xD;
          6. History of thalamic lacunar stroke&#xD;
&#xD;
          7. Modified Hachinski Ischemia Score &gt;4 points&#xD;
&#xD;
          8. History of seizure disorder requiring medication&#xD;
&#xD;
          9. History of brain surgery (for seizure disorder, aneurysms, or benign/malignant tumor)&#xD;
&#xD;
         10. History of HIV/AIDS&#xD;
&#xD;
         11. Severe untreated obstructive sleep apnea&#xD;
&#xD;
         12. Greater than three servings alcohol daily or illicit drug use&#xD;
&#xD;
         13. Major neurologic disorders other than dementia (e.g., MS, ALS)&#xD;
&#xD;
         14. Schizophrenia, bipolar disorder, other serious mental illnesses&#xD;
&#xD;
         15. Other significant medical conditions at investigators' discretion&#xD;
&#xD;
         16. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Elias Granadillo Deluque</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

